Quality of Life Research

, Volume 6, Issue 2, pp 0–0

Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy

  • J. Dancey
  • B. Zee
  • D. Osoba
  • M. Whitehead
  • F. Lu
  • L. Kaizer
  • J. Latreille
  • J. L. Pater
Article

DOI: 10.1023/A:1026442201191

Cite this article as:
Dancey, J., Zee, B., Osoba, D. et al. Qual Life Res (1997) 6: 0. doi:10.1023/A:1026442201191

Abstract

This report examines the prognostic associations between QOL scores measured by the EORTC QLQ-C30 and survival in a large heterogeneous population of cancer patients. Eight hundred and fifty-one cancer patients who were to receive chemotherapy were enrolled in two National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) antiemetic trials. All patients completed the EORTC QLQ-C30 immediately prior to their first chemotherapy. Survival data were available and obtained for 474 of 639 patients (74%). Cox's proportional hazards model was used to assess the independent impact of QOL and demographic variables on survival. Presence of metastatic disease, diagnosis of lung or ovarian cancer, ECOG performance status, global quality of life and emotional functioning were significantly associated with survival. Global QOL was predictive in all patients, in subgroups of patients with metastatic disease, with breast and lung cancer and other tumour types. In patients with low global quality of life scores, patients with low emotional functioning ratings lived longer than did patients with high emotional functioning ratings. Patients with high global QOL live significantly longer than do patients with low global QOL. The relationship between emotional functioning in patients with low global QOL and survival needs confirmation.

EORTC QLQ-C30 multicentre trials prognosis quality of life 

Copyright information

© Chapman and Hall 1997

Authors and Affiliations

  • J. Dancey
    • 1
  • B. Zee
    • 1
  • D. Osoba
    • 2
  • M. Whitehead
    • 1
  • F. Lu
    • 1
  • L. Kaizer
    • 3
  • J. Latreille
    • 1
  • J. L. Pater
    • 1
  1. 1.National Cancer Institute of Canada Clinical Trials GroupKingstonCanada
  2. 2.British Columbia Cancer Agency and University of British ColumbiaVancouverCanada
  3. 3.Credit Valley Hospital and University of TorontoMississaugaCanada

Personalised recommendations